Find participating medical centers and current study status in each of them
Find participating medical centers
-
Home
-
Search Results
- TRAVELLER
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
-
Neurodegenerative Disorder -
Alzheimer's Disease (AD)
- For Medical Professional
-
Download
Basic Details
Sponsor
Hoffmann-La Roche
Phase
Phase 3
Trial Identifier
NCT07177352, WP45722
Condition
Alzheimers Disease
Official Title
Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition
Study Summary
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
Eligibility Criteria
All
≥50 Years & ≤ 90 Years
No
Inclusion Criteria
- Ability and willingness to participate in an interventional clinical study, including meeting key eligibility criteria of linked interventional Roche AD studies (e.g., specific age ranges)
- Ability and willingness to receive information about potential eligibility in an associated interventional Roche AD study
Exclusion Criteria
- Dependency in basic activities of daily living (bADLs) due to cognitive impairment
- Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)
- Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
- History of severe, clinically significant central nervous system trauma
- Any serious medical condition that precludes a participant's safe participation and completion of a clinical study
- For participants with a clinical diagnosis of MCI or mild AD: Previous AD diagnosis based on biomarker confirmation with an approved or validated rule in method (e.g., amyloid PET or cerebrospinal fluid, blood biomarker) is exclusionary
This page summarises information from public registry websites, such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. To learn more about this study, see the For Medical Professional tab or visit one of those websites.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com